European Journal of Clinical Pharmacology

, Volume 32, Issue 6, pp 593–596 | Cite as

The pharmacokinetics of single high doses of dexamethasone in cancer patients

  • M. E. Brady
  • G. P. Sartiano
  • S. L. Rosenblum
  • N. E. Zaglama
  • C. T. Bauguess


We have given single high doses of dexamethasone phosphate by intravenous infusion as an antiemetic to 15 cancer patients receiving regimens containing cisplatin and/or doxorubicin. The patients received graded doses of dexamethasone phosphate, in the range 40–200 mg, dependent upon nausea and vomiting scores, during up to three consecutive cycles of cancer chemotherapy. Plasma and urine concentrations of dexamethasone (dexamethasone alcohol) were measured by HPLC.

The plasma concentration-time data were described by an open two-compartment model. The pharmacokinetic variables were independent of the dose of dexamethasone over the range studied. The terminal half-time was 4.0±0.4 h and the total body clearance was 3.5±0.4 ml·min−1·kg−1. The volume of the central compartment and the total apparent volume of distribution were 0.23±0.03 and 1.0±0.1 l·kg−1 respectively. Approximately 8% of the dose was excreted into the urine as dexamethasone.

Key words

dexamethasone dexamethasone phosphate, antiemetic pharmacokinetics cancer chemotherapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aapro MS, Alberts DS (1981) High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol 7: 11–14PubMedCrossRefGoogle Scholar
  2. 2.
    Markman M, Sheidler V, Ettinger DS, Quaskey SA, Mellits ED (1984) Antiemetic efficacy of dexamethasone. N Engl J Med 311: 549–552PubMedCrossRefGoogle Scholar
  3. 3.
    Zaglama NE, Rosenblum SL, Sartiano GP, Brady ME, Gonzalez MF, Valdivieso JG (1986) Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy. Oncology 43: 27–32PubMedCrossRefGoogle Scholar
  4. 4.
    Baker JJ, Lokey JL, Price NA, Bowen J, Winokur SH, (1980) Comparison of dexamethasone plus prochlorperazine to placebo plus prochorperazine as antiemetics for cancer chemotherapy. Proc. Am Ass Cancer Res Am Soc Clin Oncol 21: 339Google Scholar
  5. 5.
    Bruera ED, Roca E, Cedaro L, Chacon R, Estevez R (1983) Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep 67: 381–383PubMedGoogle Scholar
  6. 6.
    Cassileth PA, Lusk EJ, Torri S, Gerson SL (1984) Antiemetic efficacy of high-dose dexamethasone in induction therapy in acute nonlymphocytic leukemia. Ann Intern Med 100: 701–702PubMedGoogle Scholar
  7. 7.
    Kris MG, Gralla RJ, Tyson LB, Clark RA, Kelsen DP, Reilly LK, Groshen S, Bosl GJ, Kalman LA (1985) Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Cancer 55: 527–534PubMedCrossRefGoogle Scholar
  8. 8.
    Strum SB, McDermed JE, Streng BR, McDermott NM (1984) Combination metoclopramide and dexamethasone: An effective antiemetic regimen in outpatients receiving non-cisplatin chemotherapy. J Clin Oncol 2: 1057–1063PubMedGoogle Scholar
  9. 9.
    Miyabo S, Nakamura, T, Kuwazima S, Kishida S (1981) A comparison of the bioavailability and potency of dexamethasone phosphate and sulphate in man. Eur J Clin Pharmacol 20: 277–282PubMedCrossRefGoogle Scholar
  10. 10.
    Rose JQ, Yurchak AM, Meikle AW, Jusko WJ (1981) Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. J Pharmacokinet Biopharm 9: 1–14PubMedCrossRefGoogle Scholar
  11. 11.
    Tsuei SE, Moore RG, Ashley JJ, McBride WG (1979) Disposition of synthetic glucocorticoids: I. Pharmacokinetics of dexamethasone in healthy adults. J Pharmacokinet Biopharm 7: 249–264PubMedCrossRefGoogle Scholar
  12. 12.
    Metzler CM, Elfring GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30: 562CrossRefGoogle Scholar
  13. 13.
    Loo JCK, Riegelman S (1970) Assessment of pharmacokinetic constants from post infusion blood curves after IV infusion. J Pharm Sci 59: 53–55PubMedGoogle Scholar
  14. 14.
    Duggan DE, Yeh KC, Matalia N, Ditzler CA, McMahon FG (1975) Bioavailability of dexamethasone: II. Dexamethasone phosphate. Clin Pharmacol Ther 18: 330–337PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • M. E. Brady
    • 1
  • G. P. Sartiano
    • 2
    • 3
  • S. L. Rosenblum
    • 2
  • N. E. Zaglama
    • 3
  • C. T. Bauguess
    • 1
  1. 1.College of PharmacyUniversity of South CarolinaColumbiaUSA
  2. 2.Department of MedicineUniversity of South CarolinaColumbiaUSA
  3. 3.Dorn Veterans' HospitalUniversity of South CarolinaColumbiaUSA

Personalised recommendations